ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ: SCRX - News) today announced the completion of a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid. Glycopyrrolate is being studied for use by pediatric patients with chronic, moderate-to-severe drooling as a result of cerebral palsy, mental retardation, or any other neurological condition associated with drooling.
